Vanda Pharmaceuticals Inc expected to post a loss of 68 cents a share - Earnings Preview

What happened

Vanda Pharmaceuticals is expected to report quarterly results on October 28 for the period ending September 30, 2026. Analysts expect revenue to rise 23.0% to $69.202 million from $56.26 million a year ago, and a loss of 68 cents per share.

Confirmed

Global impact / market context

A loss of 68 cents per share means the company is expected to spend more than it earns on each share, which can pressure cash available. Revenue growth of 23.0% would show rising sales, but investors will compare profit progress against that growth.

Analyst inference

Analysts rate the shares a buy on average, split as 4 buy or strong buy and 1 hold. The median 12-month price target of $11.00 is about 174.3% above the last close of $4.01, suggesting analysts see room for recovery.

Analyst inference

What to watch

1. Vanda is expected to report a 23.0% revenue increase to $69.202 million, so watch whether actual sales reach that level, since slower growth would weaken the case for rising demand. Confirmed
2. Watch whether the company reports a loss near the expected 68 cents per share, because a wider loss would mean more cash used to fund operations and could affect borrowed money needs. Proposed
3. Watch whether management explains spending plans for research and development, since higher capital spending can raise costs and delay the path to profit even while revenue grows. Analyst inference

Evidence

• Original source link unavailable